Synthetic nanostructures including nucleic acids and/or other entities

Patent metadata

Field	Value
Publication number	US-10328026-B2
Application number	US-201514963881-A
Country	US
Kind code	B2
Filing date	Dec 9, 2015
Priority date	Jan 19, 2010
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

First claim

What is claimed is:

1. A nanostructure comprising an oligonucleotides adapted to regulate gene expression physisorbed to the surface of a synthetic carrier comprising a core surrounded by a lipid bilayer, and an apolipoprotein.

2. The nanostructure of claim 1 , wherein the oligonucleotide is modified with a lipid.

3. The nanostructure of claim 1 , wherein the oligonucleotide is end-modified with a cholesterol.

4. The nanostructure of claim 1 , wherein the oligonucleotide is adapted to regulate gene expression to inhibit angiogenesis.

5. The nanostructure of claim 1 , wherein the oligonucleotide is adapted to regulate gene expression to inhibit apoptosis.

6. The nanostructure of claim 1 , wherein the oligonucleotide is adapted to reduce intracellular miR-210 levels or regulate the expression of survivin.

7. The nanostructure of claim 1 , wherein the oligonucleotide is single stranded.

8. The nanostructure of claim 1 , wherein the oligonucleotide is double stranded.

9. The nanostructure of claim 1 , wherein the oligonucleotide comprises an antago-miR sequence.

10. The nanostructure of claim 1 , fwherein the nanostructure has a largest cross-sectional dimension of less than or equal to about 50 nm, 35 nm, or 30 nm.

11. The nanostructure of claim 1 , wherein the nanostructure comprises a core that is hollow or at least partially hollow.

12. The nanostructure of claim 1 , wherein the nanostructure core comprises a metal.

13. The nanostructure of claim 1 , wherein the nanostructure core comprises gold.

14. The nanostructure of claim 1 , wherein the apolipoprotcin is apolipoprotein A1.

15. The nanostructure of claim 1 , wherein the lipid bilayer comprises a phospholipid.

16. The nanostructure of claim 1 , wherein the lipid bilaycr comprises 50-200 phospholipids.

17. The nanostructure of claim 15 , wherein the phospholipid comprises:

18. The nanostructure of claim 15 , wherein the phospholipid comprises:

19. The nanostructure of claim 1 , wherein at least a portion of the lipid bilayer is covalently bound to the core.

20. The nanostructure of claim 1 , wherein at least a portion of the lipid bilayer is physisorbed to the core.

Assignees

• Univ Northwestern

Inventors

• Thaxton C Shad
• Mirkin Chad A
• Mcmahon Kaylin M
• Tripathy Sushant
• Mutharasan Raja Kannan
• Leander David M
• Luthi Andrea

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title